Published in Anticancer Drugs on January 01, 2010
Tumor biology and prognostic factors in renal cell carcinoma. Oncologist (2011) 1.62
Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res (2011) 1.51
Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. Vet Comp Oncol (2011) 1.15
The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA. PLoS One (2012) 0.95
Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy (2011) 0.91
The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma. Neurol Res (2012) 0.90
Antiangiogenic properties of substituted (Z)-(±)-2-(N-benzylindol-3-ylmethylene)quinuclidin-3-ol/one analogs and their derivatives. Bioorg Med Chem Lett (2010) 0.89
Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. J Cell Mol Med (2012) 0.88
Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitors: New Hope for Success in Multiple Sclerosis Therapy. Innov Clin Neurosci (2014) 0.86
Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT. Mol Imaging Biol (2011) 0.85
KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors. Int J Biol Sci (2014) 0.85
Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neurosci Lett (2012) 0.84
VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients. Int J Clin Exp Pathol (2014) 0.82
Response to targeted therapy in urachal adenocarcinoma. Rare Tumors (2014) 0.79
A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer. PLoS One (2014) 0.79
Exercise modulates redox-sensitive small GTPase activity in the brain microvasculature in a model of brain metastasis formation. PLoS One (2014) 0.78
Simultaneous renal clear cell carcinoma and gastrointestinal stromal tumor in one case. Urol Ann (2013) 0.77
Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib. PLoS One (2015) 0.75
Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells. Oncol Lett (2014) 0.75
Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway. Oncotarget (2016) 0.75
Metastasis to the parotid region as an initial presentation of renal cell carcinoma: A case report. Oncol Lett (2013) 0.75
Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome? Curr Neuropharmacol (2015) 0.75
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases. Mol Diagn Ther (2017) 0.75
Letter to the editor: "Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer". Invest New Drugs (2010) 1.41
Muscle metastasis of carcinoma. Clin Transl Oncol (2011) 1.17
Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol (2010) 1.13
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2009) 0.97
The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study. BMC Cancer (2009) 0.91
EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients. J Mol Diagn (2010) 0.90
Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs (2012) 0.85
The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study. BMC Cancer (2009) 0.84
Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. Clin Transl Oncol (2010) 0.84
Colorectal cancer: response to sunitinib in a heavily pretreated colorectal cancer patient. Anticancer Drugs (2010) 0.84
Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. Clin Dev Immunol (2011) 0.83
Overvaluation of the vulnerable elders survey-13 as a screening tool for vulnerability. J Clin Oncol (2011) 0.82
Glucose transporter expression and the potential role of fructose in renal cell carcinoma: A correlation with pathological parameters. Mol Med Rep (2011) 0.81
Diagnosis and current treatment of neurological paraneoplastic syndromes. Clin Transl Oncol (2006) 0.80
SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs). Clin Transl Oncol (2012) 0.78
Sunitinib-induced asthenia: from molecular basis to clinical relief. Cancer Biol Ther (2011) 0.75
[Under-use of adjuvant chemotherapy in women aged ≥70 years diagnosed with breast cancer in a university hospital]. Rev Esp Geriatr Gerontol (2011) 0.75
Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Expert Rev Anticancer Ther (2008) 0.75
Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis. Clin Transl Oncol (2008) 0.75
Patient with angina secondary to capecitabine. Clin Transl Oncol (2005) 0.75